Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H A Yu

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2019
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinibA J Schoenfeld, K C Arbour, H Rizvi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2025
Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastasesJ A Wilcox, M Y Jeng, S Tischfield, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2022
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomasP Selenica, A Marra, N J Choudhury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARDJ W Riess, H A Yu, X Le, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2024
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLCH A Yu, C Baik, D-W Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2019
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancerK Hastings, H A Yu, W Wei, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2020
COVID-19 in patients with lung cancerJ Luo, H Rizvi, I R Preeshagul, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2019
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinibA J Schoenfeld, K C Arbour, H Rizvi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2025
Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastasesJ A Wilcox, M Y Jeng, S Tischfield, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2022
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomasP Selenica, A Marra, N J Choudhury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARDJ W Riess, H A Yu, X Le, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2024
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLCH A Yu, C Baik, D-W Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2019
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancerK Hastings, H A Yu, W Wei, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2020
COVID-19 in patients with lung cancerJ Luo, H Rizvi, I R Preeshagul, et al.
Pageof 2